San Francisco, Ca., USA - Crescendo Bioscience, a molecular diagnostics company, announced that it has named Oscar Segurado as chief medical officer.
Article continues below
>
Dr. Segurado was most recently Vice President of Clinical Development and Medical Affairs at Becton Dickinson Biosciences where he established a clinical development organization and medical affairs function at the organization that was responsible for worldwide regulatory trials and investigational studies of cellular diagnostics in hematology/oncology, infectious diseases and regenerative medicine.
Prior to that, he was with Abbott Global Pharmaceutical Research and Development as Global Head of the Cardiovascular Medical Affairs group.
In addition, as Medical Director of the Immunology Clinical Development and Medical Affairs group at Abbott, Dr. Segurado contributed significantly to the establishment of HUMIRA, an anti-TNF drug, as the leading biological agent in rheumatic, GI, skin and other autoimmune diseases.
Dr. Segurado has authored more than 60 publications in medical and scientific journals including Lancet, Nature, Arthritis & Rheumatism, Journal of Immunology and Journal of Experimental Medicine.
He has also presented more than 120 abstracts at national and international medical and scientific meetings.
He is a current member of the International Council for Standardization in Hematology, the American Society of Hematology and a recipient of the Prix Galien-US Award for HUMIRA.
Dr. Segurado received his M.D. in neurology at the University of Salamanca, Spain and his Ph.D. in neuroimmunology at the University of Wuerzburg, Germany.
In addition, the company appointed David Chernoff, M.D., to the role of Senior Vice President of Medical Affairs.
Dr. Chernoff will continue to build relationships and liaison with the medical community to educate on the need for and advancement of molecular diagnostics in RA and other autoimmune diseases, and work closely with collaborators as the company grows its diagnostic portfolio.
Rebecca J. Bolce also joins the Crescendo Bioscience team as Director of Medical Affairs.
Ms. Bolce previously worked at Janssen Services, Inc. for 19 years with the last 11 years focused in rheumatology, where she led investigator-initiated and company-sponsored studies with infliximab, golimumab, and ustekinumab. ■